YCANTH (VP-102)
Molluscum Contagiosum
Key Facts
About Verrica Pharmaceuticals
Verrica Pharmaceuticals is a commercial-stage biotech focused on developing and commercializing novel treatments for high-unmet-need skin diseases. Its core achievement is the FDA approval and U.S. launch of YCANTH for molluscum contagiosum, with a Phase 3 program underway for common warts and a Phase 2 asset, VP-315, for basal cell carcinoma. The company's strategy centers on its proprietary topical and intralesional delivery platforms, targeting large patient populations with first-in-class or best-in-class therapeutic options. Recent milestones include a $50 million private placement, a Japanese launch partnership, and key leadership appointments to bolster commercialization.
View full company profileAbout Verrica Pharmaceuticals
Verrica Pharmaceuticals is a commercial-stage biotech focused on developing and commercializing novel treatments for high-unmet-need skin diseases. Its core achievement is the FDA approval and U.S. launch of YCANTH for molluscum contagiosum, with a Phase 3 program underway for common warts and a Phase 2 asset, VP-315, for basal cell carcinoma. The company's strategy centers on its proprietary topical and intralesional delivery platforms, targeting large patient populations with first-in-class or best-in-class therapeutic options. Recent milestones include a $50 million private placement, a Japanese launch partnership, and key leadership appointments to bolster commercialization.
View full company profileTherapeutic Areas
Other Molluscum Contagiosum Drugs
| Drug | Company | Phase |
|---|---|---|
| Zabalafin Hydrogel (AB-101a) | Alphyn Biologics | Phase 2 |
| YCANTH (Cantharidin) | Torii Pharmaceutical | Approved |
| Exploratory Asset | Veradermics | Discovery |
| ZELSUVMI™ (berdazimer topical gel, 10.3%) | Pelthos Therapeutics | Approved |